Though the vote was unanimous, discussions were complicated by the diversity of JN.1 viruses.
FDA panel supports switch to JN.1 for fall COVID vaccines
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Genetic vulnerability, air pollution may raise risk of COVID infection, severe outcomes
- COVID 2024-25 vaccines 33% protective against emergency room or urgent care visits, data reveal
- Paxlovid may better cut risk of severe COVID outcomes in asthma patients than molnupiravir
- US flu season shows signs of peak